In a statement, Prime Minister Keir Starmer said the "significant investment" had been "made possible by the pharmaceutical ...

Italian pharma group Chiesi has bolstered its rare disease business with an agreement to buy US biopharma KalVista Pharma and ...

GSK has had a solid start to 2026, with revenues rising ahead of analyst expectations in the first full quarter under new ...

The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur, saying this could ...

Board‑level appointments this month were thick and fast, with six Boards adding new faces as Chairperson, as well as several ...

Delivering a shared agenda for the UK’, it explored how to ensure NHS patients benefit from the latest medicines and vaccines ...

A study has found evidence that 11 cancers are becoming more common among young people in England, and points to a main ...

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging oral ...

Biofourmis has raised $300 million in fourth-round financing, sending its value rocketing to around $1.3 billion and injecting some fresh momentum into the digital health sector after a slowdown in ...

In a shock move, AstraZeneca has ditched a plan to invest £450 million ($558 million) in a new vaccine manufacturing plant in the UK, after the government reduced the offer on the table to support the ...

After years of wrangling, OxyContin manufacturer Purdue Pharma is on the brink of a bankruptcy agreement that could allow it ...

California, US AI start-up Profluent has signed a major alliance with pharma group Eli Lilly, worth up to $2.25 billion, that ...